Developing systemic oncolytic adenoviruses for multiple myeloma therapy
Multiple Myeloma is the 2nd most common haematological cancer and is currently incurable. Advances in treatment options have improved patient response rates but the final outcome remains constant with patients eventually developing treatment-resistance and succumbing to their disease. Novel therapeutic modalities are urgently needed. Oncolytic viruses are attenuated viruses that replicate in cancer cells and kill them, but do not harm normal cells. The goal of this project is to use blood compatible cancer-killing oncolytic viruses, to develop an effective targeted systemic treatment for multiple myeloma.